Literature DB >> 18633707

Increased folate intake with no changes in serum homocysteine and decreased levels of C-reactive protein in patients with inflammatory bowel diseases.

P G Chiarello1, F R O Penaforte, C C Japur, C D A S Souza, H Vannucchi, L E A Troncon.   

Abstract

In order to increase dietary folic acid intake and to improve nutritional status regarding folate by controlling homocysteine concentrations, ten patients with inflammatory bowel diseases (Crohn's disease in the colon and ulcerative colitis) received individualized nutritional guidance and were followed up as outpatients for 2 months. The following procedures were performed at the beginning of the study (T0), after 1 month (T1) and at the end of the study (T2): collection of anthropometric data (weight and height), dietary data (24 h diet recall), and blood under fasting condition for the determination of serum folic acid, homocysteine, C-reactive protein, and vitamin B12. Plasma folic acid deficiency was not detected but hyperhomocysteinemia was present in six individuals and C-reactive protein (CRP) was increased (>0.5 mg/dl) in seven patients. After the patients were instructed there was a significant increase in vitamin B6 intake (about 35%) and in folate intake (49.6%). Mean plasma levels of folic acid, homocysteine, and vitamin B12 did not change, but there was a significant decrease of CRP at T1, 0.36 mg dl(-1) on average (P = 0.01), which was maintained at T2. We conclude that the increased folate intake reported by this group of patients was not reflected in improved serum concentrations of folic acid and homocysteine. However, the guidelines for the patients probably induced them to choose a more adequate diet, providing nutrients that help control the inflammatory process.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18633707     DOI: 10.1007/s10620-008-0398-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  32 in total

1.  C-reactive protein and monitoring the activity of Crohn's disease.

Authors:  Levent Filik; Ulku Dagli; Aysel Ulker
Journal:  Adv Ther       Date:  2006 Jul-Aug       Impact factor: 3.845

2.  Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease.

Authors:  A Papa; V De Stefano; S Danese; P Chiusolo; S Persichilli; I Casorelli; B Zappacosta; B Giardina; A Gasbarrini; G Leone; G Gasbarrini
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

3.  Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease.

Authors:  Asif Mahmood; Jane Needham; Jeanne Prosser; Jason Mainwaring; Tim Trebble; Gillian Mahy; John Ramage
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-07       Impact factor: 2.566

4.  Fruit and vegetable intakes, C-reactive protein, and the metabolic syndrome.

Authors:  Ahmad Esmaillzadeh; Masoud Kimiagar; Yadollah Mehrabi; Leila Azadbakht; Frank B Hu; Walter C Willett
Journal:  Am J Clin Nutr       Date:  2006-12       Impact factor: 7.045

5.  Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease.

Authors:  M R Malinow; P B Duell; D L Hess; P H Anderson; W D Kruger; B E Phillipson; R A Gluckman; P C Block; B M Upson
Journal:  N Engl J Med       Date:  1998-04-09       Impact factor: 91.245

6.  High prevalence of hyperchomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications?

Authors:  M Cattaneo; M Vecchi; M L Zighetti; S Saibeni; I Martinelli; P Omodei; P M Mannucci; R de Franchis
Journal:  Thromb Haemost       Date:  1998-10       Impact factor: 5.249

7.  Association of increased levels of homocysteine and peripheral arterial disease in a Japanese-Brazilian population.

Authors:  L Garofolo; N Barros; F Miranda; V D'Almeida; L C Cardien; S R Ferreira
Journal:  Eur J Vasc Endovasc Surg       Date:  2007-05-07       Impact factor: 7.069

Review 8.  C-reactive protein as a marker for inflammatory bowel disease.

Authors:  Séverine Vermeire; Gert Van Assche; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2004-09       Impact factor: 5.325

9.  Colonic mucosal concentrations of folate correlate well with blood measurements of folate status in persons with colorectal polyps.

Authors:  Y I Kim; K Fawaz; T Knox; Y M Lee; R Norton; S Arora; L Paiva; J B Mason
Journal:  Am J Clin Nutr       Date:  1998-10       Impact factor: 7.045

Review 10.  Laboratory markers in IBD: useful, magic, or unnecessary toys?

Authors:  S Vermeire; G Van Assche; P Rutgeerts
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

View more
  4 in total

1.  Folic acid inhibits lipopolysaccharide-induced inflammatory response in RAW264.7 macrophages by suppressing MAPKs and NF-κB activation.

Authors:  Dan Feng; Yan Zhou; Min Xia; Jing Ma
Journal:  Inflamm Res       Date:  2011-04-29       Impact factor: 4.575

2.  Folic Acid Supplementation Delays Atherosclerotic Lesion Development by Modulating MCP1 and VEGF DNA Methylation Levels In Vivo and In Vitro.

Authors:  Shanshan Cui; Wen Li; Xin Lv; Pengyan Wang; Yuxia Gao; Guowei Huang
Journal:  Int J Mol Sci       Date:  2017-05-05       Impact factor: 5.923

3.  Folic acid protects against lipopolysaccharide-induced preterm delivery and intrauterine growth restriction through its anti-inflammatory effect in mice.

Authors:  Mei Zhao; Yuan-Hua Chen; Xu-Ting Dong; Jun Zhou; Xue Chen; Hua Wang; Shu-Xian Wu; Mi-Zhen Xia; Cheng Zhang; De-Xiang Xu
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

4.  Folic Acid Represses Hypoxia-Induced Inflammation in THP-1 Cells through Inhibition of the PI3K/Akt/HIF-1α Pathway.

Authors:  Xiaoyan Huang; Zhiying He; Xinwei Jiang; Mengjun Hou; Zhihong Tang; Xiaozhou Zhen; Yuming Liang; Jing Ma
Journal:  PLoS One       Date:  2016-03-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.